National Health Research Institutes 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SB01 / Sinphar Pharma
NCT01151930: Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

No Longer Available
N/A
NA
SCB01A
SynCore Biotechnology Co., Ltd.
Malignant Solid Tumour
 
 
ABT-101 / Anbogen Therap
NCT05532696: Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Recruiting
1/2
61
RoW
ABT-101, DBPR112
Anbogen Therapeutics, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
11/26
05/27
prusogliptin (DBPR108) / CSPC Pharma
ChiCTR2000029574: A Phase III Clinical Trial for DBPR108 Tablets in the Treatment of Type 2 Diabetes

Not yet recruiting
3
750
 
Phase A (Weeks 1-24): DBPR108 100mg and placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg ;Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg and Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg ;Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg and placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
Peking University First Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd., CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus
 
 
ChiCTR2000032566: A Phase III clinical trial of DBPR108 tablets combined with metformin hydrochloride tablets in the treatment of type 2 diabetes

Not yet recruiting
3
210
 
Treatment period (1w-24w): DBPR108 tablets and metformin hydrochloride tablets ;Treatment period (1w-24w): DBPR108 placebo and metformin hydrochloride tablets
Beijing Union Medical College Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd., CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus
 
 
NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Not yet recruiting
3
815
NA
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes
10/26
11/26
NCT04859426: A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Completed
1
24
RoW
DBPR108 tablets, DBPR108
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Hepatic Impairment
05/22
05/22
NCT05150626: A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects

Completed
1
21
RoW
DBPR108 tablets
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
06/22
07/22
T-1301 / Taivex Therapeutics Corporation, National Health Research Institutes
NCT05156203: Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Recruiting
1
30
RoW
T-1301 Capsules
Taivex Therapeutics Corporation
Advanced Solid Tumor, Lymphoma
01/27
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SB01 / Sinphar Pharma
NCT01151930: Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

No Longer Available
N/A
NA
SCB01A
SynCore Biotechnology Co., Ltd.
Malignant Solid Tumour
 
 
ABT-101 / Anbogen Therap
NCT05532696: Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Recruiting
1/2
61
RoW
ABT-101, DBPR112
Anbogen Therapeutics, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
11/26
05/27
prusogliptin (DBPR108) / CSPC Pharma
ChiCTR2000029574: A Phase III Clinical Trial for DBPR108 Tablets in the Treatment of Type 2 Diabetes

Not yet recruiting
3
750
 
Phase A (Weeks 1-24): DBPR108 100mg and placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg ;Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg and Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg ;Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg and placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
Peking University First Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd., CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus
 
 
ChiCTR2000032566: A Phase III clinical trial of DBPR108 tablets combined with metformin hydrochloride tablets in the treatment of type 2 diabetes

Not yet recruiting
3
210
 
Treatment period (1w-24w): DBPR108 tablets and metformin hydrochloride tablets ;Treatment period (1w-24w): DBPR108 placebo and metformin hydrochloride tablets
Beijing Union Medical College Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd., CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus
 
 
NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Not yet recruiting
3
815
NA
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes
10/26
11/26
NCT04859426: A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Completed
1
24
RoW
DBPR108 tablets, DBPR108
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Hepatic Impairment
05/22
05/22
NCT05150626: A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects

Completed
1
21
RoW
DBPR108 tablets
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
06/22
07/22
T-1301 / Taivex Therapeutics Corporation, National Health Research Institutes
NCT05156203: Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Recruiting
1
30
RoW
T-1301 Capsules
Taivex Therapeutics Corporation
Advanced Solid Tumor, Lymphoma
01/27
12/27

Download Options